Free Trial

Sage Therapeutics (SAGE) Stock Price, News & Analysis

Sage Therapeutics logo
$9.20 +0.05 (+0.49%)
As of 01:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Sage Therapeutics Stock (NASDAQ:SAGE)

Key Stats

Today's Range
$9.14
$9.24
50-Day Range
$6.38
$9.30
52-Week Range
$4.62
$13.47
Volume
686,760 shs
Average Volume
1.73 million shs
Market Capitalization
$576.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.75
Consensus Rating
Reduce

Company Overview

Sage Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

SAGE MarketRank™: 

Sage Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 339th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sage Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.94, and is based on no buy ratings, 16 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Sage Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Sage Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sage Therapeutics are expected to grow in the coming year, from ($3.52) to ($2.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sage Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sage Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sage Therapeutics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sage Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.53% of the float of Sage Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sage Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sage Therapeutics has recently increased by 0.96%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Sage Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sage Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.53% of the float of Sage Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sage Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sage Therapeutics has recently increased by 0.96%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Sage Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Sage Therapeutics this week, compared to 9 articles on an average week.
  • Search Interest

    3 people have searched for SAGE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sage Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of Sage Therapeutics is held by insiders.

  • Percentage Held by Institutions

    99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sage Therapeutics' insider trading history.
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Stock News Headlines

Scotiabank Downgrades Sage Therapeutics (SAGE)
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Headlines

SAGE Stock Analysis - Frequently Asked Questions

Sage Therapeutics' stock was trading at $5.43 at the start of the year. Since then, SAGE shares have increased by 69.5% and is now trading at $9.2050.

Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its quarterly earnings results on Tuesday, April, 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by $0.02. Sage Therapeutics's quarterly revenue was up 78.0% on a year-over-year basis.
Read the conference call transcript
.

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sage Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
4/29/2025
Today
7/09/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SAGE
CIK
1597553
Employees
690
Year Founded
N/A

Price Target and Rating

High Price Target
$16.00
Low Price Target
$4.00
Potential Upside/Downside
-4.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.94
Research Coverage
17 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$400.67 million
Net Margins
-747.63%
Pretax Margin
-747.63%

Debt

Sales & Book Value

Annual Sales
$41.24 million
Price / Cash Flow
N/A
Book Value
$7.60 per share
Price / Book
1.21

Miscellaneous

Free Float
59,177,000
Market Cap
$573.60 million
Optionable
Optionable
Beta
0.29

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:SAGE) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners